Other

Alfa Laval Corporation Ab

Pharmacia Lkb Biotechnology Ab

Biostapro Ab

Martin K Lindberg

Magnus Hook

Lars Christer Signas

Torkel Mikael Wadstrom

Gunnar Froman

Bengt Guss

Mathias Uhlen

Jan-Ingmar Flock

Lars Frykberg

Christer Signas

Hans Jonsson

Martin Nilsson

Sven Lofdahl

John Sjoquist

Lech Switalski

Joseph Patti

A new fibrinogen binding protein or polypeptide originating from coagulase negativebiotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negativeand a vaccine composition, comprising the protein or DNA.

Antibodies to a fibrinogen binding protein of staphylococcus epidermidis

The present invention relates to a new recombinant DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having collagen binding properties.

Collagen binding protein as well as its preparation

The present invention relates to a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

Fibronectin binding protein as well as its preparation

The present invention relates to a new recombinant hybrid-DNA-molecule comprising nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

A method of producing and selectively isolating a desired protein or polypeptide or derivative thereof by constructing a recombinant vector comprising a DNA sequence coding for said desired protein or polypeptide operatively linked to a DNA sequence coding for protein A or an active polypeptide fragment thereof or any other macromolecule capable of binding to the constant regions of immunoglobulins, such that said DNA sequences together code for an IgG-binding fusion product between said desired protein or polypeptide and said protein A, active polypeptide fragment thereof or macromolecule; transforming a compatible host with said recombinant vector such that the combined DNA sequences coding for said fusion protein or polypeptide can be expressed by the host, and culturing the transformed host in a suitable growth medium to produce said fusion protein or polypeptide; selectively isolating said fusion protein or polypeptide by adsorption to an IgG-supporting carrier material; and optionally desorbing said fusion protein or polypeptide from said IgG-supporting carrier, said fusion protein or polypeptide coded for by said combined DNA-sequence optionally comprising a unique cleavage site between said protein A part and said desired protein or polypeptide part, said desired protein or polypeptide part then being cleaved off from the rest of the fusion protein or polpeptide either while the latter is adsorbed to the IgG-supporting carrier or after desorption thereof from the carrier. Also a hybrid vector for use herein, a method and an expression vector for its preparation and a host organism transformed by said hybrid vector are disclosed.

Method of producing and isolating IGG-binding protein a fusion peptides

Growing community of inventors

Upsala, Sweden

Martin K Lindberg